5-氟尿嘧啶、表柔比星和丝裂霉素C（FEM）作为辅助治疗在淋巴结阳性、根治性切除的胃癌患者中的应用：一家综合医院经验的调查
Use of 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant therapy in node-positive, radically-resected gastric cancer patients: survey of a general hospital experience.
作者信息
Caffo O, Ambrosini G, Amichetti M, Brugnara S, Graiff C, Robbiati S F, Galligioni E
机构信息
Department of Medical Oncology, S. Chiara Hospital, Largo Medaglie D'Oro, 38100 Trento, Italy.
出版信息
Oncol Rep. 1998 Nov-Dec;5(6):1465-9. doi: 10.3892/or.5.6.1465.
Between 1/1986 and 6/1996, 37 consecutive patients affected by node-positive gastric cancer (GC) were treated with radical surgery and received 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant treatment. Only 57% of the patients received all six cycles and the reasons for treatment withdrawal were mainly related to concomitant pathologies and prolonged leukopenia. After a median follow-up of 39 months, the 3-year disease-free survival, disease-related survival and overall survival were 75.8%, 83.7% and 78.6% respectively. A statistically significant difference in survival was found in the subgroup of patients receiving more than three courses of treatment.
在1986年1月至1996年6月期间，37例连续的淋巴结阳性胃癌（GC）患者接受了根治性手术，并接受5-氟尿嘧啶、表柔比星和丝裂霉素C（FEM）作为辅助治疗。只有57%的患者接受了全部六个周期的治疗，治疗中断的原因主要与合并症和长期白细胞减少有关。中位随访39个月后，3年无病生存率、疾病相关生存率和总生存率分别为75.8%、83.7%和78.6%。在接受超过三个疗程治疗的患者亚组中发现了生存方面的统计学显著差异。
Zotero 插件